Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

Last year was a big year for Fairbanks Museum, highlighted by major moments in the museum’s 136-year history, but in 2025, the museum will focus on the smaller things, both literally and ...

Vito Coppola has revealed he's set to miss out on the start of the Strictly Come Dancing Live tour as he has been hit with an injury blow. The professional dancer recently excitedly revealed that ...

Elsewhere in the world of failed trials, biotech Denali Therapeutics has reported that a Phase II/III trial of DNL343 for amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint.

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a placebo, and therefore ...

According to a press release from Denali Therapeutics Inc., the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was change in disease severity measured ...

Denali Therapeutics recently disclosed the outcomes of its HEALEY trial, which evaluated DNL343, an agonist of eIF2B intended for the treatment of amyotrophic lateral sclerosis (ALS). The trial failed ...

The revision followed the announcement that Denali's DNL343, an eIF2B inhibitor, did not achieve the primary or key secondary endpoints in the phase 2/3 HEALEY trial for amyotrophic lateral sclerosis ...